However, venetoclax treatment of tumor-bearing mice or AML patients failed to deplete DCs, and Bcl2-/- de-ini-DCs that were transferred into NSCLC-bearing mice infiltrated tumors more efficiently than their WT counterparts. This evidence concerns the gene BCL2 and neoplasm.